Publication details
Léčba nemocných s nemalobuněčným karcinomem a mutacemi genu receptoru epidermálního růstového faktoru
| Title in English | Treatment of patients with non-small cell cancer and EGFR mutation |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.scopus.com/record/display.uri?eid=2-s2.0-85057434039&origin=resultslist&sort=plf-f&src=s&st1=Skrickova+j&st2=&sid=30478f9a865dd0b4c43b44f213418963&sot=b&sdt=b&sl=24&s=AUTHOR-NAME%28Skrickova+j%29&relpos=5&citeCnt=0&searchTerm= |
| Keywords | EGFR mutation; Non-small cell lung cancer; Tyrosinkinase inhibitors |
| Description | Considering treatment after establishing the diagnosis of non-small cell lung cancer (NSCLC), it is currently attempted to select a drug that is shown to be effective in a tumor that carries certain morphological and / or molecular genetic features. At the turn of the third millennium, biological therapy preparations began to be applied in NSCLC treatment that selectively interfered with intracellular processes in the tumor cell. Biologic therapies act on tumor cells by a mechanism different from standard chemotherapy. Biologically targeted treatment is sometimes also called targeted molecular therapy. The epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity that plays an important role in cell cycle regulation, cell differentiation, proliferation, and survival. Its sustained activation, along with activation of subsequent signaling pathways, can contribute to malignant transformation and stimulate processes leading to growth, invasion, metastasis and angiogenesis. One way to influence its function and thereby achieve antitumor effect is to block its intracellular tyrosine kinase component. In NSCLC patients with a genetic abnormality - EGFR gene mutation - the treatment with tyrosine kinase (TKI) EGFR is most effective. |